
Brookside Capital
North America, California, United States, San Francisco
Description
They design, implement, and manage custom tailored portfolios of liquid assets for high net worth investors.
Investor Profile
Brookside Capital has backed more than 45 startups, with 0 new investments in the last 12 months alone. The firm has led 10 rounds, about 22% of its total and boasts 31 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series C, Series B, Series D rounds (top funding stages).
- Majority of deals are located in United States, China, Singapore.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
Stage Focus
- Series C (24%)
- Series B (18%)
- Series D (18%)
- Series E (9%)
- Private Equity (9%)
- Series Unknown (7%)
- Series F (4%)
- Post Ipo Equity (4%)
- Series A (4%)
- Series G (2%)
Country Focus
- United States (84%)
- China (9%)
- Singapore (2%)
- Indonesia (2%)
- South Korea (2%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Therapeutics
- Biopharma
- Medical
- Enterprise Software
- Genetics
- Video
- Software
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.